Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
ZYUS Life Sciences ( (TSE:ZYUS) ) has issued an update.
ZYUS Life Sciences Corporation announced the closing of an additional CA$0.5 million secured loan from an independent director, which will be used for general working capital and to advance clinical research activities. This loan, subject to TSX Venture Exchange approval, includes the issuance of common share purchase warrants and reflects the company’s strategy to strengthen its financial position and support the development of its lead drug product candidate, Trichomylin® softgel capsules.
The most recent analyst rating on (TSE:ZYUS) stock is a Buy with a C$1.50 price target. To see the full list of analyst forecasts on ZYUS Life Sciences stock, see the TSE:ZYUS Stock Forecast page.
More about ZYUS Life Sciences
ZYUS Life Sciences Corporation is a Canadian-based life sciences company specializing in the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. The company is committed to advancing non-opioid-based pharmaceutical solutions through rigorous scientific exploration and clinical research, aiming to secure regulatory approval and intellectual property protection to enhance shareholder value.
Average Trading Volume: 11,213
Technical Sentiment Signal: Sell
Current Market Cap: C$45.99M
See more insights into ZYUS stock on TipRanks’ Stock Analysis page.